Market Indices
Latest News
 |
| ||
| ||
|
Price Targets
from Macquarie issued a price target of $2.00 for EVO on 2026-07-15 06:51:00.The adjusted price target was set to $2.00.At the time of the announcement, EVO was...
July 15, 2026 EVO -11.93%
from Scotiabank issued a price target of $52.00 for GFI on 2026-07-14 16:34:01.The adjusted price target was set to $52.00.At the time of the announcement, GFI was...
July 14, 2026 GFI -0.60%
Market Movers
| Top Gainers (%) | |||||||||||||||||||
| LGHL Lion Group Holding Ltd. | 2.42
11.01% | ||||||||||||||||||
| ACH Accendra Health, Inc. | 3.61
7.12% | ||||||||||||||||||
| OPRA Opera Limited | 20.13
7.07% | ||||||||||||||||||
| RDHL RedHill Biopharma Ltd. | 0.74
6.64% | ||||||||||||||||||
| HKD AMTD Digital Inc. | 1.62
6.58% | ||||||||||||||||||
| NBTX Nanobiotix S.A. | 41.64
6.36% | ||||||||||||||||||
| LXEH Lixiang Education Holding | 1.36
6.25% | ||||||||||||||||||
| JHX James Hardie Industries p | 25.78
6.13% | ||||||||||||||||||
Annual/Quarterly Reports Summary
Summit Therapeutics Inc. (SMMT) Quarterly Report: What Does It Reveal About Their Sector Performance
May 1, 2025 SMMT 1.11%
In a landscape of rising revenues and increasing operational costs, the company navigates challenges with a focus on innovation and sustainability. Despite a dip in net income and profit declines...
February 5, 2025 TEVA -1.12%
In a year marked by resilience, the company celebrated record revenues of $25 billion, driven by strong ticket sales and operational efficiency. With a focus on North America, it reduced...
January 27, 2025 TEVA -1.12%